What is the Upadacitinib?

Upadacitinib is , while it's Molecular Formula is C17H19F3N6O. Upadacitinib also known as ABT-494, is a potent and selective Janus kinase (JAK) 1 inhibitor being developed for the treatment of several autoimmune disorders, Janus kinase inhibitors for rheumatoid arthritis.

What is the CAS number for Upadacitinib?

The CAS number of Upadacitinib is 1310726-60-3.

What is Upadacitinib (1310726-60-3) used for?

Upadacitinib (ABT-494) is a JAK1 selective inhibitor being investigated to treat rheumatoid arthritis, Crohn's disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA Giant Cell Arteritis and Takayasu Arteritis.

What is the Upadacitinib?

Upadacitinib is , while it's Molecular Formula is C17H19F3N6O. Upadacitinib also known as ABT-494, is a potent and selective Janus kinase (JAK) 1 inhibitor being developed for the treatment of several autoimmune disorders, Janus kinase inhibitors for rheumatoid arthritis.

What is the CAS number for Upadacitinib?

The CAS number of Upadacitinib is 1310726-60-3.

What is Upadacitinib (1310726-60-3) used for?

Upadacitinib (ABT-494) is a JAK1 selective inhibitor being investigated to treat rheumatoid arthritis, Crohn's disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA Giant Cell Arteritis and Takayasu Arteritis.

Product Class

1310726-60-3

Product Name：Upadacitinib
Molecular Formula：C17H19F3N6O
Purity：99%
Molecular Weight：380.373

Inquiry

Product Details:

CasNo： 1310726-60-3

Molecular Formula： C17H19F3N6O

Buy Reliable Quality Upadacitinib 1310726-60-3 On Stock

Molecular Formula:C17H19F3N6O
Molecular Weight:380.373
PKA:11.89±0.60(Predicted)
PSA：78.32000
Density:1.56±0.1 g/cm3(Predicted)
LogP:3.23670

Upadacitinib 1310726-60-3 Usage

Description

Upadacitinib, sold under the brand name Rinvoq, is an immunosuppressant medication approved by the FDA for treating various conditions. As a second-generation Janus kinase (JAK) inhibitor specifically targeting the JAK1 enzyme, Upadacitinib works by reducing the activity of the immune system.

Uses

It is used to treat the following conditions:

Moderate to severe rheumatoid arthritis
Active psoriatic arthritis
Ankylosing spondylitis
Non-radiographic axial spondyloarthritis
Moderate to severe ulcerative colitis
Moderate to severe Crohn's disease
Atopic dermatitis
Upadacitinib's mechanism of action involves blocking the activity of Janus kinases, which play a role in immune system signaling. It is specifically indicated for cases of moderate to severe rheumatoid arthritis that do not respond to first-line therapy.

1310726-60-3 Relevant articles

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

Prof Gerd R Burmester, MD Prof Joel M Kremer, MD Prof Filip Van den Bosch, MD Alan Kivitz, MD Prof Louis Bessette, MD Yihan Li, PhD

The Lancet, VOLUME 391, ISSUE 10139, P2503-2512, JUNE 23, 2018

Using interactive response technology, we randomly assigned patients receiving stable background csDMARDs (2:2:1:1) to receive a once-daily extended-release formulation of upadacitinib 15 mg or 30 mg, or placebo, for 12 weeks. Patients, investigators, and the funder were masked to allocation.

Development of a Scalable Enantioselective Synthesis of JAK Inhibitor Upadacitinib

Bhagavatula, Lakshmi,Christesen, Alan,Dunn, Travis B.,Ickes, Andrew,Kotecki, Brian J.,Marek, James C.,Morrill, Westin H.,Moschetta, Eric,Mulhern, Mathew,Rasmussen, Michael,Reynolds, Troy,Rozema, Michael J.,Yu, Su

, (2021/10/21)

Process development of a six-stage synth...

PYRROLIDINE COMPOUNDS, ITS SALT AND USE IN THE PREPARATION OF UPADACITINIB THEREOF

-

, (2021/01/29)

The present invention relates to process...

1310726-60-3 Upstream products

753-90-2
trifluoroethylamine
530-62-1
1,1'-carbonyldiimidazole
1428243-26-8
(3R,4S)-benzyl 3-(2-bromoacetyl)-4-ethylpyrrolidine-1-carboxylate
1201186-54-0
2-bromo-5-(p-toluenesulfonyl)-5H-pyrrolo[2,3-b]pyrazine

Relevant Products

Pralsetinib
CAS：2097132-94-8
Resmetirom
CAS：920509-32-6
Apalutamide
CAS：956104-40-8